Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AttackMS: Natalizumab in early Multiple Sclerosis or CIS
NCT05418010Phase 2Recruiting
- Sponsor
- Queen Mary University of London
- Start
- Dec 2022
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of natalizumab in multiple sclerosis (MS) and clinically isolated syndrome (CIS) (2 arms), sponsored by Queen Mary University of London. Primary endpoint: Magnetization Transfer Ratio at 12 weeks. Started Dec 2022; status: recruiting.
02
Drugs
natalizumab
03
Conditions
multiple sclerosis (MS)clinically isolated syndrome (CIS)
Beyond the preview
Go deeper on NCT05418010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05418010.